Health in the Millenium Development Goals: Millenium Development Goals, Targets and Indicators Related to Health. World Health Organization; 2004.

Glossary of Globalization, Trade and Health Terms: Health Transition. World Health Organization; 2007.

Beaglehole, R, Irwin, A, Prentice, T. The World Health Report 2004: Changing History. Geneva, Switzerland: The World Health Organization; 2004.Google Scholar

Coulter, SL, Cecil, B. Assessing the Value of Health Care in Tennessee. Chattanooga: Blue Cross Blue Shield of Tennessee; 2003.Google Scholar

Breast Cancer Facts and Figures 2005–2006. Atlanta, GA: American Cancer Society, Inc.; 2005. http://www.cancer.org/downloads/STT/CAFF2005BrF.pdf

Peters, WP, Ross, M, Vredenburgh, JJ, Meisenberg, B, Marks, L, Winer, E, et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. Journal Of Clinical Oncology: Official Journal Of The American Society Of Clinical Oncology. 1993 June; 11(6): 1132–43.CrossRefGoogle ScholarPubMed

Groopman, J. Bone marrow transplant: a healing hell. The New Yorker. 1998 October 19: 34–9.Google Scholar

Mello, MM, Brennan, TA. The controversy over high-dose chemotherapy with autologous bone marrow transplant for breast cancer. Health Affairs (Project Hope). 2001 Sep–Oct; 20(5): 101–17.CrossRefGoogle ScholarPubMed

Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence – SEER 13 Regs Public-Use, Nov 2005 Sub (1992–2003) and SEER 9 Regs Public-Use, Nov 2005 Sub (1973–2003), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2006, based on the November 2005 submission.

Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Mortality – All COD, Public-Use With State, Total U.S. for Expanded Races/Hispanics (1990–2003) and All COD, Public-Use With State, Total U.S. (1969–2003), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2006. Underlying mortality data provided by NCHS (www.cdc.gov/nchs).

Silverthorn, DU. Human Physiology: An Integrated Approach. 2nd edn. Upper Saddle River, NJ: Prentice Hall; 2001.Google Scholar

,American Cancer Society. Detailed Guide: Breast Cancer: How is Breast Cancer Staged? Sep 18 2006 [cited 2007]. Available from: http://www.cancer.org/docroot/CRI/content/CRI_2_4_3X_How_is_breast_cancer_staged_5.asp

Walker, F, Roethke, SK, Martin, G. An overview of the rationale, process, and nursing implications of peripheral blood stem cell transplantation. Cancer Nursing. 1994 Oct 10; 17(2): 141–8.CrossRefGoogle ScholarPubMed

Hansson, M, Svensson, A, Engervall, P. Autologous peripheral blood stem cells: collection and processing. Medical Oncology. 1996 Jun; 13(2): 71–9.CrossRefGoogle Scholar

Leukemia, Lymphoma, Myeloma, Facts and Statistics 2006–2007. White Plains, NY: Leukemia and Lymphoma Society; 2007.

White, K. Notebook: bone marrow transplant for breast cancer is questioned on basis of incomplete data. Journal of Women's Health and Gender-Based Medicine. 1999; 8(5): 577–82.CrossRefGoogle Scholar

Brockstein, BE, Williams, SF. High-dose chemotherapy with autologous stem cell rescue for breast cancer: yesterday, today, and tomorrow. Stem Cells. 1996; 14: 79–89.CrossRefGoogle Scholar

Abegunde, D, Beaglehole, R, Durivage, S, Epping-Jordan, J, Mathers, C, Shengelia, B, et al. Preventing Chronic Diseases: A Vital Investment. Geneva, Switzerland: World Health Organization; 2005.Google Scholar

Aetna, . Breast cancer: high-dose chemotherapy with autologous stem cell support. Clinical Policy Bulletins 2005 October 5 [available from: http://www.aetna.com/cpb/data/CPBA0507.html].Google Scholar

Bezwoda, WR, Seymour, L, Dansey, RD. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. Journal Of Clinical Oncology: Official Journal Of The American Society Of Clinical Oncology. 1995 Oct; 13(10): 2483–9.CrossRefGoogle ScholarPubMed

Tallman, MS, Gray, R, Robert, NJ, LeMaistre, CF, Osborne, CK, Vaughan, WP, et al. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. The New England Journal Of Medicine. 2003 Jul 3; 349(1): 17–26.CrossRefGoogle ScholarPubMed

Bezwoda, WR. Randomised, controlled trial of high dose chemotherapy versus standard dose chemotherapy for high risk, surgically treated, primary breast cancer. Proceedings of the American Society of Clinical Oncology. 1999; 18: 2a.Google Scholar

Grady, D. Doubts raised on a breast cancer procedure. New York Times. 1999 April 16; Sect. A1.Google Scholar

Silberner, J. Morning Show: breast cancer. National Public Radio. 1999 April 16. http://www.npr.org/templates/story/story.php?storyId=1049404.

Anthem, . Insurance payments for bone marrow transplantation in metastatic breast cancer. The New England Journal of Medicine. 2000 April 13; 342(15): 1138–9.Google Scholar

New audit uncovers scientific misconduct in 1995 South African study on metastatic breast cancer. American Society of Clinical Oncology. 2001 April 26.

Horton, R. After Bezwoda. Lancet. 2000 Mar 18; 355(9208): 942–3.CrossRefGoogle ScholarPubMed

Rodenhuis, S, Bontenbal, M, Beex, LV, Wagstaff, J, Richel, DJ, Nooij, MA, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. The New England Journal Of Medicine. 2003 Jul 3; 349(1): 7–16.CrossRefGoogle ScholarPubMed

Stadtmauer, EA, O'Neill, A, Goldstein, LJ, Crilley, PA, Mangan, KF, Ingle, JN, et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. The New England Journal of Medicine. 2000 Apr 13; 342(15): 1069–76.CrossRefGoogle ScholarPubMed

Antman, KH. Randomized trials of high dose chemotherapy for breast cancer. Biochimica Et Biophysica Acta. 2001 Mar 21; 1471(3): M89–98.Google ScholarPubMed

Frazier, HS, Mosteller, F. Medicine Worth Paying For: Assessing Medical Innovations. Cambridge, Mass.: Harvard University Press; 1995.Google Scholar

Ioannidis, JP. Contradicted and initially stronger effects in highly cited clinical research. JAMA: The Journal Of The American Medical Association. 2005 Jul 13; 294(2): 218–28.CrossRefGoogle ScholarPubMed

Face to Face with Chronic Desease: Maria's Story: Fighting Cancer. World Health Organization, 2005.

Mello, M. M. and Brennan, T. A.. The controversy over high-dose chemotherapy with autologous bone marrow transplant for breast cancer. Health Affairs, 20:5 (2001), 101–17CrossRefGoogle ScholarPubMed